Basic safety assessments indicated that gastrointestinal adverse events, mainly nausea and diarrhea, have been dose-dependent but typically delicate and transient. These conclusions recognized the therapeutic window and informed dose selection for subsequent Stage 3 trials.Quite a few human cytokines will develop a pleasant reaction in mouse mobile